Aggamin Biologics
Aggamin Biologics is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Aggamin Biologics is a technology company.
Aggamin Biologics is a biotechnology company headquartered in New York City, focused on developing biologic drugs and innovative therapies for vascular diseases, with a primary emphasis on preeclampsia—a condition affecting 5% of pregnancies and imposing significant costs on the U.S. healthcare system.[1][2][3][6] It serves healthcare providers and patients by addressing unmet medical needs in women's health, particularly through research and clinical development of treatments that improve health outcomes for critical vascular conditions.[2][3][4][5] The company, formerly known as Aggamin Pharmaceuticals and founded in 2009, operates as a private entity with under 25 employees and revenue below $5 million, showing early-stage growth in the biotech sector.[2][3]
Aggamin Biologics traces its roots to 2009, when it was established as Aggamin Pharmaceuticals LLC, initially structured as a bio-medical company targeting unmet needs in women's health, with preeclampsia as the lead focus.[3][5] Founder Paul Kussie, linked to the company's early vision, drove its emphasis on vascular therapies from its New York base, evolving from general biologic drug development to specialized research in preeclampsia and related vascular diseases.[3] Pivotal early efforts centered on securing SBIR funding and building a foundation in drug development, setting the stage for clinical advancements amid a landscape of high unmet needs in maternal health.[5]
Aggamin Biologics rides the wave of advancing biotech innovations in maternal and vascular health, capitalizing on growing awareness of preeclampsia as a major public health issue amid rising global pregnancy complications.[2][6] Timing aligns with surging investments in women's health post-pandemic, where unmet needs in biologics for vascular diseases create market tailwinds, including SBIR support and demand for cost-saving therapies.[5] It influences the ecosystem by pioneering targeted drugs, competing with giants like Genentech and CSL Behring while filling gaps in preeclampsia treatment, potentially transforming healthcare delivery for high-risk pregnancies worldwide.[3][6]
Aggamin Biologics is poised for clinical milestones, with potential Phase I/II trials advancing its preeclampsia pipeline amid biotech funding rebounds and precision medicine trends.[3][4][6] Rising focus on maternal health tech—driven by AI diagnostics and biologics—will shape its path, possibly attracting partnerships or acquisitions from larger pharma players. Its influence could expand by setting standards in vascular therapies, evolving from niche innovator to key ecosystem player, directly addressing the high-level challenge of revolutionizing care for critical diseases like preeclampsia.[2][6]